Phentolamine mesilate NEW

‌Phentolamine Mesilate | 🔥 Non-Selective α-Blocker | 💊 Rapid Vasodilator for Hypertension & Raynaud’s | ✅ USP/EP Grade‌

‌🌐 Product Overview‌

Phentolamine Mesilate is a ‌non-selective α-adrenergic receptor antagonist‌ that rapidly reverses vasoconstriction and lowers blood pressure‌13. It is clinically used to manage ‌hypertensive crises‌ and ‌Raynaud’s syndrome‌ by blocking α1/α2 receptors, improving blood flow and reducing ischemia‌14. With ‌>99% HPLC-verified purity‌, it meets stringent pharmacopeial standards for therapeutic applications‌24.

‌⚡ Key Benefits‌

• ‌⏱️ Rapid Onset‌

  : Achieves blood pressure reduction within 

  ‌30 minutes‌ of administration‌.
• ‌🎯 Dual α1/α2 Blockade‌

  : Ensures balanced vasodilation and reduced cardiac workload‌34.

• ‌🧪 High Purity‌

  : ‌HPLC >99%‌ and ‌GC-MS validated‌, minimizing impurities‌.

‌🏥 Applications‌

1. ‌Hypertensive Emergencies‌

   : Controls acute blood pressure spikes‌13.

2. ‌Raynaud’s Disease‌

   : Alleviates vasospasm-induced pain and ischemia‌12.

3. ‌Diagnostic Testing‌

   : Identifies pheochromocytoma via catecholamine reversal‌15.

‌✅ Quality Certifications‌

• Complies with ‌USP/EP‌ monographs for APIs‌.

• Rigorous ‌residual solvent analysis‌ (GC-MS) and ‌batch-specific COA‌ provided‌.

‌📈 Market Trends‌

The global ‌hypertension drug market‌ is projected to grow at ‌5.8% CAGR (2025–2030)‌‌6, driven by rising cardiovascular disease prevalence (affecting ‌1.3 billion adults‌ worldwide)‌5. Phentolamine remains a critical agent in emergency and niche vascular therapies‌16.

‌Keywords‌: Non-selective alpha blocker, vasodilator drug, hypertensive crisis treatment, Raynaud’s syndrome medication, USP-grade API

Citations: ‌12 | Updated: Feb 2025